SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2025)
Historic Retained Earnings for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to -$94.0 million.
- SAB Biotherapeutics' Retained Earnings rose 1663.61% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.0 million, marking a year-over-year increase of 1663.61%. This contributed to the annual value of -$124.2 million for FY2024, which is 3786.81% down from last year.
- Latest data reveals that SAB Biotherapeutics reported Retained Earnings of -$94.0 million as of Q3 2025, which was up 1663.61% from -$139.5 million recorded in Q2 2025.
- Over the past 5 years, SAB Biotherapeutics' Retained Earnings peaked at $3.0 million during Q1 2021, and registered a low of -$139.5 million during Q2 2025.
- Moreover, its 5-year median value for Retained Earnings was -$62.1 million (2023), whereas its average is -$66.1 million.
- In the last 5 years, SAB Biotherapeutics' Retained Earnings plummeted by 441973.26% in 2022 and then soared by 1663.61% in 2025.
- SAB Biotherapeutics' Retained Earnings (Quarter) stood at -$29.1 million in 2021, then tumbled by 64.34% to -$47.9 million in 2022, then plummeted by 88.14% to -$90.1 million in 2023, then crashed by 37.87% to -$124.2 million in 2024, then increased by 24.27% to -$94.0 million in 2025.
- Its last three reported values are -$94.0 million in Q3 2025, -$139.5 million for Q2 2025, and -$129.4 million during Q1 2025.